Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gut microbiome manipulation and vaccine immune responses
NL-OMON44814Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2015
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of human rotavirus RIX4414 strain vaccine, ciprofloxacin, vancomycin, metronidazole, tetanus toxoid and 1 more in rotaviral diarrhea, Tetanus and pneumococcal disease (3 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: 28-day post-vaccination anti-rotavirus IgA serum response. Started Sep 2015; status: active, not recruiting.
02
Drugs
human rotavirus RIX4414 strain vaccineciprofloxacinvancomycinmetronidazoletetanus toxoid
03
Conditions
rotaviral diarrheaTetanuspneumococcal disease
Beyond the preview
Go deeper on NL-OMON44814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44814.